{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:09:30Z","timestamp":1786594170050,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"JSPS Grants-in-Aid","award":["<GN1>16K19454) to K.O. and"],"award-info":[{"award-number":["<GN1>16K19454) to K.O. and"]}]},{"name":"JSPS Grants-in-Aid","award":["<GN1>15H04830) to K.O. and K.K"],"award-info":[{"award-number":["<GN1>15H04830) to K.O. and K.K"]}]},{"name":"Boehringer-Ingelheim, Japan"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.lungcan.2019.08.019","type":"journal-article","created":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T11:17:46Z","timestamp":1566299866000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL\/6J mice"],"prefix":"10.1016","volume":"136","author":[{"given":"Hisao","family":"Higo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5180-3933","authenticated-orcid":false,"given":"Kadoaki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Makimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Nishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroe","family":"Kayatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2134-2865","authenticated-orcid":false,"given":"Kiichiro","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Kiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.lungcan.2019.08.019_bib0005","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"10089","key":"10.1016\/j.lungcan.2019.08.019_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.lungcan.2019.08.019_bib0015","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2019.08.019_bib0020","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S1470-2045(16)30562-9","article-title":"Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial","volume":"17","author":"Drilon","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2019.08.019_bib0025","series-title":"Contribution of Nationwide Genome Screening in Japan (LC-SCRUM-Japan) to the Development of Precision Medicine for Non-small Cell Lung Cancer","author":"Seto","year":"2018"},{"issue":"6","key":"10.1016\/j.lungcan.2019.08.019_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/cas.12941","article-title":"Gene aberrations for precision medicine against lung adenocarcinoma","volume":"107","author":"Saito","year":"2016","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2019.08.019_bib0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2012.43.3912","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease","volume":"31","author":"Ohashi","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.08.019_bib0040","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1038\/s41598-018-20326-z","article-title":"MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib","volume":"8","author":"Ninomiya","year":"2018","journal-title":"Sci. Rep."},{"issue":"27","key":"10.1016\/j.lungcan.2019.08.019_bib0045","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2019.08.019_bib0050","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2019.08.019_bib0055","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"5827","key":"10.1016\/j.lungcan.2019.08.019_bib0060","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"issue":"52","key":"10.1016\/j.lungcan.2019.08.019_bib0065","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"Bean","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"22","key":"10.1016\/j.lungcan.2019.08.019_bib0070","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2019.08.019_bib0075","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"issue":"31","key":"10.1016\/j.lungcan.2019.08.019_bib0080","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.lungcan.2019.08.019_bib0085","doi-asserted-by":"crossref","first-page":"S1769","DOI":"10.1016\/j.jtho.2017.09.379","article-title":"OA 09.06 a phase ib trial of Savolitinib plus gefitinib for Chinese patients with EGFR-Mutant MET-Amplified advanced NSCLC","volume":"12","author":"Fang","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2019.08.019_bib0090","doi-asserted-by":"crossref","first-page":"S1768","DOI":"10.1016\/j.jtho.2017.09.377","article-title":"OA 09.03 TATTON ph ib expansion cohort: Osimertinib plus Savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI","volume":"12","author":"Ahn","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"31","key":"10.1016\/j.lungcan.2019.08.019_bib0095","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase Ib\/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-Mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.08.019_bib0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/JTO.0000000000000434","article-title":"Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer study Group Trial 1001","volume":"10","author":"Ichihara","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.08.019_bib0105","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2017.11.025","article-title":"A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404","volume":"115","author":"Ninomiya","year":"2018","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2019.08.019_bib0110","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1158\/0008-5472.CAN-08-4204","article-title":"Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo","volume":"69","author":"Ichihara","year":"2009","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2019.08.019_bib0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1158\/1535-7163.MCT-12-0885","article-title":"Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model","volume":"12","author":"Ninomiya","year":"2013","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.lungcan.2019.08.019_bib0120","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/1878-0261.12063","article-title":"Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo","volume":"11","author":"Kudo","year":"2017","journal-title":"Mol. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2019.08.019_bib0125","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1111\/j.1349-7006.2008.00875.x","article-title":"Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter","volume":"99","author":"Ohashi","year":"2008","journal-title":"Cancer Sci."},{"issue":"17","key":"10.1016\/j.lungcan.2019.08.019_bib0130","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/0008-5472.CAN-08-4205","article-title":"Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice","volume":"69","author":"Ohashi","year":"2009","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.lungcan.2019.08.019_bib0135","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1101\/gad.1417406","article-title":"Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors","volume":"20","author":"Politi","year":"2006","journal-title":"Genes Dev."},{"issue":"6","key":"10.1016\/j.lungcan.2019.08.019_bib0140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2006.04.022","article-title":"The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies","volume":"9","author":"Ji","year":"2006","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.lungcan.2019.08.019_bib0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.lungcan.2019.08.019_bib0150","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2019.08.019_bib0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151539","article-title":"Doxycycline promotes carcinogenesis &amp; metastasis via chronic inflammatory pathway: an in vivo approach","volume":"11","author":"Nanda","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.lungcan.2019.08.019_bib0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","article-title":"Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib","volume":"88","author":"Wu","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2019.08.019_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178676","article-title":"The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer","volume":"12","author":"Chang","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.lungcan.2019.08.019_bib0170","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1541-7786.MCR-09-0460","article-title":"Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs","volume":"8","author":"Mink","year":"2010","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2019.08.019_bib0175","doi-asserted-by":"crossref","first-page":"E227","DOI":"10.1002\/ijc.27403","article-title":"Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer","volume":"131","author":"Chung","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2019.08.019_bib0180","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","article-title":"Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment","volume":"28","author":"Haratani","year":"2017","journal-title":"Ann. Oncol."},{"issue":"7527","key":"10.1016\/j.lungcan.2019.08.019_bib0185","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nature13992","article-title":"A comparative encyclopedia of DNA elements in the mouse genome","volume":"515","author":"Yue","year":"2014","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.lungcan.2019.08.019_bib0190","doi-asserted-by":"crossref","first-page":"E6409","DOI":"10.1073\/pnas.1613601113","article-title":"Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma","volume":"113","author":"McFadden","year":"2016","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7636","key":"10.1016\/j.lungcan.2019.08.019_bib0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature20792","article-title":"Genome-wide in vivo screen identifies novel host regulators of metastatic colonization","volume":"541","author":"van der Weyden","year":"2017","journal-title":"Nature"},{"issue":"1\u20132","key":"10.1016\/j.lungcan.2019.08.019_bib0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1242\/dmm.003681","article-title":"Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma","volume":"3","author":"Politi","year":"2010","journal-title":"Dis. Model. Mech."},{"issue":"10","key":"10.1016\/j.lungcan.2019.08.019_bib0205","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1158\/0008-5472.CAN-12-4136","article-title":"Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells","volume":"73","author":"Shien","year":"2013","journal-title":"Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219306208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:21:50Z","timestamp":1569543710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219306208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":41,"alternative-id":["S0169500219306208"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.08.019","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL\/6J mice","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}